- Home
- LGCY vs CUE Comparison
LGCY vs CUE Comparison
Compare LGCY & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- CUE
- Stock Information
- Founded
- LGCY 2009
- CUE 2014
- Country
- LGCY United States
- CUE United States
- Employees
- LGCY N/A
- CUE N/A
- Industry
- LGCY
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- CUE Health Care
- Exchange
- LGCY NYSE
- CUE Nasdaq
- Market Cap
- LGCY 107.0M
- CUE 94.4M
- IPO Year
- LGCY 2024
- CUE 2018
- Fundamental
- Price
- LGCY $7.45
- CUE $1.32
- Analyst Decision
- LGCY Strong Buy
- CUE Strong Buy
- Analyst Count
- LGCY 2
- CUE 5
- Target Price
- LGCY $10.65
- CUE $5.00
- AVG Volume (30 Days)
- LGCY 102.6K
- CUE 195.8K
- Earning Date
- LGCY 02-13-2025
- CUE 03-10-2025
- Dividend Yield
- LGCY N/A
- CUE N/A
- EPS Growth
- LGCY 44.62
- CUE N/A
- EPS
- LGCY 0.58
- CUE N/A
- Revenue
- LGCY $52,722,310.00
- CUE $9,532,000.00
- Revenue This Year
- LGCY $33.77
- CUE $73.11
- Revenue Next Year
- LGCY $19.89
- CUE $11.02
- P/E Ratio
- LGCY $12.93
- CUE N/A
- Revenue Growth
- LGCY 32.68
- CUE 149.53
- 52 Week Low
- LGCY $3.60
- CUE $0.45
- 52 Week High
- LGCY $10.37
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- CUE 48.32
- Support Level
- LGCY N/A
- CUE $1.22
- Resistance Level
- LGCY N/A
- CUE $1.54
- Average True Range (ATR)
- LGCY 0.00
- CUE 0.11
- MACD
- LGCY 0.00
- CUE -0.01
- Stochastic Oscillator
- LGCY 0.00
- CUE 35.29
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.